ECSP14017269A - Compuestos para tratar la atrofia muscular espinal - Google Patents
Compuestos para tratar la atrofia muscular espinalInfo
- Publication number
- ECSP14017269A ECSP14017269A ECIEPI201417269A ECPI201417269A ECSP14017269A EC SP14017269 A ECSP14017269 A EC SP14017269A EC IEPI201417269 A ECIEPI201417269 A EC IEPI201417269A EC PI201417269 A ECPI201417269 A EC PI201417269A EC SP14017269 A ECSP14017269 A EC SP14017269A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- muscular atrophy
- spinal muscular
- treat spinal
- treat
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000002320 spinal muscular atrophy Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan en la presente compuestos, composiciones de los mismos y usos con los mismos para el tratamiento de la atrofia muscular espinal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597523P | 2012-02-10 | 2012-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14017269A true ECSP14017269A (es) | 2015-09-30 |
Family
ID=48948163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201417269A ECSP14017269A (es) | 2012-02-10 | 2014-09-04 | Compuestos para tratar la atrofia muscular espinal |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9586955B2 (es) |
| EP (2) | EP3406252B1 (es) |
| JP (2) | JP6092897B2 (es) |
| KR (2) | KR102137087B1 (es) |
| CN (3) | CN108299314B (es) |
| AR (1) | AR092794A1 (es) |
| AU (2) | AU2013216870B2 (es) |
| BR (1) | BR112014019750B1 (es) |
| CA (1) | CA2863874C (es) |
| CL (1) | CL2014002100A1 (es) |
| CO (1) | CO7061082A2 (es) |
| CR (1) | CR20140376A (es) |
| DK (1) | DK2812004T3 (es) |
| EA (2) | EA037123B1 (es) |
| EC (1) | ECSP14017269A (es) |
| ES (1) | ES2697174T3 (es) |
| HU (1) | HUE039779T2 (es) |
| IL (2) | IL233959A (es) |
| MA (1) | MA35920B1 (es) |
| MX (2) | MX354074B (es) |
| NZ (1) | NZ628186A (es) |
| PE (1) | PE20142364A1 (es) |
| PH (2) | PH12018501711B1 (es) |
| PL (1) | PL2812004T3 (es) |
| SG (2) | SG11201404713PA (es) |
| TR (1) | TR201813877T4 (es) |
| TW (2) | TWI629274B (es) |
| UA (1) | UA116981C2 (es) |
| WO (1) | WO2013119916A2 (es) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10327940B2 (en) | 2008-11-09 | 2019-06-25 | 3D Systems, Inc. | Spiral brace |
| EP2797592B1 (en) | 2011-12-30 | 2019-08-28 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| CA2862084C (en) | 2012-01-26 | 2021-05-11 | Ptc Therapeutics, Inc. | 1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy |
| UA116981C2 (uk) | 2012-02-10 | 2018-06-11 | ПіТіСі ТЕРАП'ЮТІКС, ІНК. | Сполуки для лікування спінальної м'язової атрофії |
| EP2819519B1 (en) | 2012-03-01 | 2019-10-23 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| MX358514B (es) | 2012-03-23 | 2018-08-24 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MD20150056A2 (ro) * | 2012-12-24 | 2015-09-30 | Ramot At Tel-Aviv University Ltd | Agenţi pentru tratarea bolilor genetice cauzate de mutaţii nonsens şi metode de identificare a acestora |
| WO2015024876A2 (en) * | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| WO2015105657A1 (en) * | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| PL3663296T3 (pl) | 2014-05-15 | 2023-08-07 | F. Hoffmann-La Roche Ag | Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
| WO2016054615A2 (en) | 2014-10-03 | 2016-04-07 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| WO2016066142A1 (en) * | 2014-11-01 | 2016-05-06 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
| US20170368608A1 (en) * | 2015-01-05 | 2017-12-28 | Sikorsky Aircraft Corporation | Integrated vibration damper for additively manufactured structure and method |
| EP3298017B1 (en) * | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| IL308174A (en) | 2015-10-09 | 2024-01-01 | Univ Southampton | Modulation of gene expression and screening for deregulated protein expression |
| AU2016351919B2 (en) * | 2015-11-12 | 2020-11-12 | F. Hoffmann-La Roche Ag | Compounds for treating amyotrophic lateral sclerosis |
| EP4360707A3 (en) * | 2015-11-12 | 2024-08-07 | F. Hoffmann-La Roche AG | Compositions for treating spinal muscular atrophy |
| PT3386591T (pt) | 2015-12-09 | 2020-10-01 | Cadent Therapeutics Inc | Moduladores de recetores nmda heteroaromáticos e suas utilizações |
| PL3386511T3 (pl) | 2015-12-10 | 2021-11-08 | Ptc Therapeutics, Inc. | Sposoby leczenia choroby huntingtona |
| CN108137579B (zh) | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
| KR102604132B1 (ko) | 2015-12-14 | 2023-11-17 | 콜드스프링하버러보러토리 | 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| CN108473510B (zh) * | 2016-04-28 | 2021-10-29 | 豪夫迈·罗氏有限公司 | 制备2-吡唑并[1,5-a]吡嗪-2-基吡啶并[1,2-a]嘧啶-4-酮的方法 |
| WO2017218884A1 (en) | 2016-06-16 | 2017-12-21 | Ionis Pharmaceuticals, Inc. | Combinations for the modulation of smn expression |
| EP3544435A4 (en) * | 2016-11-28 | 2020-11-04 | PTC Therapeutics, Inc. | RNA SPLICE MODULATION PROCESSES |
| WO2018119374A1 (en) * | 2016-12-22 | 2018-06-28 | Cadent Therapeutics | Nmda receptor modulators and uses thereof |
| KR20200033249A (ko) | 2017-06-05 | 2020-03-27 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| US11608501B2 (en) | 2017-06-14 | 2023-03-21 | Ptc Therapeutics, Inc. | Methods for modifying RNA splicing |
| US11395822B2 (en) | 2017-06-28 | 2022-07-26 | Ptc Therapeutics, Inc. | Methods for treating Huntington's disease |
| CN111182898B (zh) * | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| IL321831A (en) | 2017-08-25 | 2025-08-01 | Stoke Therapeutics Inc | Antisense oligomers for the treatment of conditions and diseases |
| CN111132981B (zh) * | 2017-09-22 | 2023-10-31 | 豪夫迈·罗氏有限公司 | 制备吡啶并[1,2-a]嘧啶-4-酮衍生物的方法 |
| EP4494706A3 (en) | 2017-10-23 | 2025-06-04 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases |
| EA202092001A1 (ru) | 2018-03-27 | 2021-01-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни гентингтона |
| BR112020022512A2 (pt) | 2018-05-04 | 2021-05-04 | Stoke Therapeutics, Inc. | métodos e composições para tratamento de doença de armazenamento de éster de colesteril |
| AU2019294482B2 (en) | 2018-06-27 | 2022-09-01 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| EA202190116A1 (ru) | 2018-06-27 | 2021-08-30 | Реборна Биосайенсиз, Инк. | Агент для профилактики или лечения спинальной мышечной атрофии |
| SG11202012674PA (en) | 2018-06-27 | 2021-01-28 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for treating huntington's disease |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| IL280474B2 (en) | 2018-08-03 | 2023-09-01 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and their uses |
| US20210355509A1 (en) * | 2018-08-07 | 2021-11-18 | The Children's Hospital Of Philadelphia | Alternative splicing regulation of gene expression and therapeutic methods |
| EP3920915A4 (en) | 2019-02-05 | 2022-10-05 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICE |
| CN114126613A (zh) | 2019-02-05 | 2022-03-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| EP3921311A4 (en) | 2019-02-06 | 2022-11-09 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICE |
| CN119528905A (zh) | 2019-02-06 | 2025-02-28 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| WO2021111124A1 (en) | 2019-12-02 | 2021-06-10 | Storm Therapeutics Limited | Polyheterocyclic compounds as mettl3 inhibitors |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| WO2021021775A1 (en) | 2019-07-31 | 2021-02-04 | Teva Pharmaceuticals International Gmbh | Solid state forms of risdiplam and process for preparation thereof |
| CN110540535B (zh) * | 2019-10-23 | 2020-07-31 | 上海再启生物技术有限公司 | 适合放大制备4-(6-氨基吡啶-3-基)取代哌啶的工艺方法 |
| CN111116576A (zh) * | 2019-12-01 | 2020-05-08 | 北京师范大学 | 一种喹嗪酮类化合物及其制备方法 |
| AU2021214076A1 (en) | 2020-01-28 | 2022-08-04 | Protego Biopharma, Inc. | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| AU2021218807A1 (en) * | 2020-02-12 | 2022-09-15 | The Children's Hospital Of Philadelphia | Compositions and methods for inducible alternative splicing regulation of gene expression |
| BR112022017107A2 (pt) | 2020-02-28 | 2022-11-16 | Remix Therapeutics Inc | Derivados de piridazina para modulação de splicing de ácido nucleico |
| IL295956A (en) | 2020-02-28 | 2022-10-01 | Remix Therapeutics Inc | Heterocyclic amides and their use for modulating splicing |
| IL295955A (en) | 2020-02-28 | 2022-10-01 | Remix Therapeutics Inc | Compounds and methods for modulating splicing |
| WO2021174174A1 (en) | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Thiophenyl derivatives useful for modulating nucleic acid splicing |
| CN115279379B (zh) | 2020-02-28 | 2025-05-09 | Ionis制药公司 | 用于调节smn2的化合物和方法 |
| WO2021207550A1 (en) | 2020-04-08 | 2021-10-14 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20230159496A1 (en) | 2020-04-08 | 2023-05-25 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| JP2023532331A (ja) | 2020-07-02 | 2023-07-27 | リミックス セラピューティクス インコーポレイテッド | 核酸をスプライシングするため及び増殖性疾患を処置するための修飾因子としての５－［５－（ピペリジン－４－イル）チエノ［３，２－ｃ］ピラゾール－２－イル］インダゾール誘導体及び関連する化合物並びにスプライシングを調節するための化合物及び方法 |
| KR20230051168A (ko) | 2020-07-02 | 2023-04-17 | 레믹스 테라퓨틱스 인크. | 2-(인다졸-5-일)-6-(피페리딘-4-일)-1,7-나프티리딘 유도체, 및 핵산 스플라이싱의 조절제로서의 및 증식성 질환의 치료를 위한 관련 화합물 |
| WO2022070071A1 (en) * | 2020-09-30 | 2022-04-07 | Janssen Biotech, Inc. | Dihydroorotate dehydrogenase inhibitors |
| IL305203A (en) | 2021-03-17 | 2023-10-01 | Hoffmann La Roche | New histories of thiazolopyrimidines |
| TW202321206A (zh) | 2021-07-28 | 2023-06-01 | 美商普羅泰戈生物製藥股份有限公司 | 轉甲狀腺素蛋白穩定化合物 |
| WO2023034836A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| AU2022339925A1 (en) | 2021-08-30 | 2024-03-14 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| PE20251687A1 (es) | 2021-08-30 | 2025-07-02 | Remix Therapeutics Inc | Compuestos y metodos para modular splicing |
| WO2023034827A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023034833A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| JP2024538096A (ja) | 2021-10-13 | 2024-10-18 | リミックス セラピューティクス インコーポレイテッド | 核酸スプライシングを調節するための化合物及び方法 |
| EP4416156A1 (en) | 2021-10-13 | 2024-08-21 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
| US20250109140A1 (en) | 2022-01-05 | 2025-04-03 | Remix Theraputics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| TW202346305A (zh) | 2022-01-05 | 2023-12-01 | 美商雷密克斯醫療公司 | 用於調節剪切之化合物及方法 |
| US20250092065A1 (en) | 2022-01-05 | 2025-03-20 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2024251925A1 (en) * | 2023-06-09 | 2024-12-12 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
| CN117263936B (zh) * | 2023-11-21 | 2024-02-23 | 中国中医科学院医学实验中心 | 一种咪唑并[1, 2-a]吡啶衍生物及其制备方法和在中枢神经系统渗透性HDAC6抑制药物中的应用 |
| WO2025233837A1 (en) | 2024-05-07 | 2025-11-13 | Takeda Pharmaceutical Company Limited | 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558618A (en) * | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| US4342870A (en) * | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| JPS56150091A (en) | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5726182A (en) * | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
| AU4231293A (en) * | 1992-05-13 | 1993-12-13 | E.I. Du Pont De Nemours And Company | Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides |
| AU6153096A (en) | 1995-06-06 | 1996-12-24 | Abbott Laboratories | Quinolizinone type compounds |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| AU5991699A (en) * | 1998-09-21 | 2000-04-10 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
| WO2001030757A1 (en) * | 1999-10-28 | 2001-05-03 | Microcide Pharmaceuticals, Inc. | Drug discharge pump inhibitors |
| AU3042601A (en) * | 2000-01-24 | 2001-07-31 | Thrombogenix Pty Ltd | Therapeutic morpholino-substituted compounds |
| EP1389463A4 (en) * | 2001-04-26 | 2008-09-17 | Daiichi Seiyaku Co | MEDICAMENT FOR INHIBITING A DRUG REMOVAL PUMP |
| MXPA04005510A (es) | 2001-12-07 | 2006-02-24 | Vertex Pharma | Compuestos basados en pirimidina utiles como inhibidores de gsk-3. |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| ATE548354T1 (de) | 2002-07-24 | 2012-03-15 | Ptc Therapeutics Inc | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen |
| KR20060069356A (ko) | 2003-06-20 | 2006-06-21 | 카이론 코포레이션 | 항암제로서 피리디노[1,2-α]피리미딘-4-온 화합물 |
| ES2292130T3 (es) * | 2004-05-04 | 2008-03-01 | Warner-Lambert Company Llc | Pirido(2,3-d)pirimidin-7-onas pirrolil-sustituidas y derivados de las mismas como agentes terapeuticos. |
| AU2006206446A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8110681B2 (en) * | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| EP2138493A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| US8986935B2 (en) | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| WO2011050245A1 (en) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| WO2011062853A1 (en) * | 2009-11-20 | 2011-05-26 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| US20130012506A1 (en) * | 2010-01-13 | 2013-01-10 | Zaesung No | Anti-infective pyrido (1,2-a) pyrimidines |
| EP2797592B1 (en) | 2011-12-30 | 2019-08-28 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| CA2862084C (en) | 2012-01-26 | 2021-05-11 | Ptc Therapeutics, Inc. | 1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy |
| UA116981C2 (uk) * | 2012-02-10 | 2018-06-11 | ПіТіСі ТЕРАП'ЮТІКС, ІНК. | Сполуки для лікування спінальної м'язової атрофії |
| EP2819519B1 (en) | 2012-03-01 | 2019-10-23 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| MX358514B (es) | 2012-03-23 | 2018-08-24 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| PL3663296T3 (pl) | 2014-05-15 | 2023-08-07 | F. Hoffmann-La Roche Ag | Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
-
2013
- 2013-02-08 UA UAA201409921A patent/UA116981C2/uk unknown
- 2013-02-08 MX MX2014009696A patent/MX354074B/es active IP Right Grant
- 2013-02-08 WO PCT/US2013/025292 patent/WO2013119916A2/en not_active Ceased
- 2013-02-08 CN CN201810234432.7A patent/CN108299314B/zh active Active
- 2013-02-08 PE PE2014001250A patent/PE20142364A1/es active IP Right Grant
- 2013-02-08 EA EA201792465A patent/EA037123B1/ru unknown
- 2013-02-08 KR KR1020147025275A patent/KR102137087B1/ko active Active
- 2013-02-08 EP EP18179491.8A patent/EP3406252B1/en active Active
- 2013-02-08 EP EP13747100.9A patent/EP2812004B1/en active Active
- 2013-02-08 PL PL13747100T patent/PL2812004T3/pl unknown
- 2013-02-08 CN CN202411603136.1A patent/CN119528903A/zh active Pending
- 2013-02-08 PH PH1/2018/501711A patent/PH12018501711B1/en unknown
- 2013-02-08 US US14/377,531 patent/US9586955B2/en active Active
- 2013-02-08 ES ES13747100T patent/ES2697174T3/es active Active
- 2013-02-08 JP JP2014556711A patent/JP6092897B2/ja active Active
- 2013-02-08 HU HUE13747100A patent/HUE039779T2/hu unknown
- 2013-02-08 NZ NZ628186A patent/NZ628186A/en unknown
- 2013-02-08 TR TR2018/13877T patent/TR201813877T4/tr unknown
- 2013-02-08 DK DK13747100.9T patent/DK2812004T3/en active
- 2013-02-08 CA CA2863874A patent/CA2863874C/en active Active
- 2013-02-08 SG SG11201404713PA patent/SG11201404713PA/en unknown
- 2013-02-08 EA EA201491505A patent/EA029542B1/ru not_active IP Right Cessation
- 2013-02-08 AU AU2013216870A patent/AU2013216870B2/en active Active
- 2013-02-08 CN CN201380019368.6A patent/CN104349777B/zh active Active
- 2013-02-08 KR KR1020207020788A patent/KR102341596B1/ko active Active
- 2013-02-08 SG SG10201609188WA patent/SG10201609188WA/en unknown
- 2013-02-08 BR BR112014019750-4A patent/BR112014019750B1/pt active IP Right Grant
- 2013-02-14 AR ARP130100450 patent/AR092794A1/es active IP Right Grant
- 2013-02-18 TW TW106106161A patent/TWI629274B/zh active
- 2013-02-18 TW TW102105672A patent/TWI585085B/zh active
-
2014
- 2014-08-05 IL IL233959A patent/IL233959A/en active IP Right Grant
- 2014-08-07 PH PH12014501786A patent/PH12014501786A1/en unknown
- 2014-08-08 CL CL2014002100A patent/CL2014002100A1/es unknown
- 2014-08-08 CR CR20140376A patent/CR20140376A/es unknown
- 2014-08-11 MX MX2022011699A patent/MX2022011699A/es unknown
- 2014-08-28 MA MA37313A patent/MA35920B1/fr unknown
- 2014-09-04 EC ECIEPI201417269A patent/ECSP14017269A/es unknown
- 2014-09-09 CO CO14198817A patent/CO7061082A2/es unknown
-
2016
- 2016-08-26 US US15/248,052 patent/US9879007B2/en active Active
-
2017
- 2017-02-09 JP JP2017022640A patent/JP6363744B2/ja active Active
- 2017-06-22 AU AU2017204248A patent/AU2017204248B2/en active Active
- 2017-08-17 IL IL254045A patent/IL254045B/en active IP Right Grant
- 2017-12-20 US US15/848,075 patent/US20180105526A1/en not_active Abandoned
-
2019
- 2019-08-15 US US16/541,401 patent/US10851101B2/en active Active
-
2020
- 2020-10-05 US US17/062,853 patent/US11753407B2/en active Active
-
2023
- 2023-07-26 US US18/359,209 patent/US20240067646A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| MX358514B (es) | Compuestos para tratar la atrofia muscular espinal. | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| EA201491412A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
| BR112014021531A8 (pt) | composto, composição farmacêutica e usos dos mesmos | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| CR20150316A (es) | Compuestos y sus métodos de empleo | |
| NI201500140A (es) | Compuestos y composiciones terapéuticos | |
| MX376008B (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| MX2015012867A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| CR20150067A (es) | Pirazoles sustituidos como bloqueadores del canal de calcio tipo n | |
| NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
| CY1120204T1 (el) | Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο | |
| GEP201706710B (en) | Imidazopyridazine derivatives as gabaa receptor modulators | |
| MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
| UY34725A (es) | Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos. | |
| MX2015003701A (es) | Composiciones para tratamiento. | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| CR20150070A (es) | Pirrolopirazoles como bloqueadores del canal de calcio tipo n | |
| DOP2015000176A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. |